Sanofi Opens Partnering Office in Stevenage Bioscience Catalyst

Collaboration Reinforces Commitment to Bringing Breakthrough Science to the Clinic and Accelerating Translation of Innovation into Treatments for Patients

Guildford,UK – April 13th , 2016Sanofi today announced the creation of a partnering office at Stevenage Bioscience Catalyst to engage and collaborate with the network of bioscience companies and academia that form part of the UK’s vibrant life sciences ecosystem.  This collaboration reflects Sanofi’s commitment to open innovation and collaboration that is necessary to accelerate the translation of transformative innovation.

 “Sanofi is committed to bringing breakthrough science to the clinic and to accelerate the translation of innovation into effective treatments for patients,” said Yvonne Naughton, Head of External Science and Partnering, UK & Ireland at Sanofi.  “At Sanofi we recognise that the next big discovery may come from outside of our own laboratories. Core to our strategy is to build strong relationships with biotechnology organisations, research institutes and academic centres.”

The collaboration with Stevenage Bioscience Catalyst is one example of partnering initiatives being led within the UK and Ireland by Sanofi’s External Science & Partnering function. Sanofi works with partners to develop mutually beneficial relationships with the singular focus of advancing high-quality scientific research with the goal of improving the lives of patients in areas of high unmet need.  Key areas of research interest to Sanofi include diabetes, cardiovascular disease, rare diseases, vaccines, immunology, oncology, multiple sclerosis, neurodegenerative and infectious diseases. 

 “Sanofi is a fantastic addition to the thriving ecosystem developing here, and we aredelighted that it recognises the value of being part of our innovation-focused community,” added Martino Picardo, CEO of Stevenage Bioscience Catalyst. “Sanofi’s expertise in a range of therapeutic and technical areas will play an important role as we and our tenants continue to focus on better healthcare driven by collaboration. With Sanofi’s focus on transformative new medicines and openness to external innovation, there is a strong strategic fit with SBC and we anticipate a long and fruitful relationship.”


About Stevenage Bioscience Catalyst

Stevenage Bioscience Catalyst (SBC) opened as the UK’s first open innovation biomedical campus in 2012, and combines a unique blend of infrastructure and virtual networks to drive collaboration. Backed by a novel partnership between Government, GlaxoSmithKline and the Wellcome Trust, the remit was, and remains, to catalyse innovation for patient benefit in a phased development. SBC has a strong commitment to companies that focus on high quality science and share its vision, and its development of activity clusters and direct access to the expertise of a major pharmaceutical company are among its unique characteristics. There is start-up and grow-on space for companies, plus a commercially focused management team viewed as a leader in UK incubation. With Phase 1 complete, Phase 2 is in development for the continuation of the collaborative vision, with a focus on open innovation and convergent medical technologies. Co-located with GlaxoSmithKline in Stevenage, Stevenage Bioscience Catalyst is located close to both London and Cambridge. For more information, please go to

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable,investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including postmarketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.



Sanofi UK Media Relations

Michael Szumera

Head of Communications, UK & Ireland

Tel.  +44 (0) 1483 55 4076

Mob. +44 (0) 7736 728058


Stevenage Bioscience Catalyst

Emma Palmer Foster

Strategic Communications

Tel.+44 (0) 7880 787185